Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felix-Martin Werner

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Current Pharmaceutical Design|June 20, 2019
Neural Networks in Neurological and Psychiatric DiseasesFelix-Martin Werner
Current Pharmaceutical Design|January 29, 2016
Serotonergic Drugs: Agonists/Antagonists at Specific Serotonergic Subreceptors for the Treatment of Cognitive, Depressant and Psychotic Symptoms in Alzheimer's DiseaseFelix-Martin Werner, Rafael Covenas
Current Pharmaceutical Design|April 11, 2019
Therapeutic Effect of Novel Antidepressant Drugs Acting at Specific Receptors of Neurotransmitters and NeuropeptidesFelix-Martin Werner, Rafael Coveñas
The International Journal of Neuroscience|June 30, 2010
Classical neurotransmitters and neuropeptides involved in major depression: a reviewFelix-Martin Werner, Rafael Coveñas
Central Nervous System Agents in Medicinal Chemistry|January 27, 2026
Clinical Effects of Recently Developed Antipsychotic Drugs in SchizophreniaFelix-Martin Werner, Rafael Coveñas
Current Medicinal Chemistry|October 3, 2013
Classical neurotransmitters and neuropeptides involved in major depression in a multi-neurotransmitter system: a focus on antidepressant drugsFelix-Martin Werner, R Coveñas
Therapeutics and Clinical Risk Management|November 21, 2015
New developments in the management of schizophrenia and bipolar disorder: potential use of cariprazineFelix-Martin Werner, Rafael Coveñas
Current Pharmaceutical Design|December 11, 2020
The Novel Antipsychotic Drug Cariprazine and Cognition Enhancing Drugs: Indications for their Use as the Add-on Therapy in SchizophreniaFelix-Martin Werner, Rafael Coveñas
Current Drug Discovery Technologies|October 24, 2019
Risperidone: A Commentary on Drug ProfilingFelix-Martin Werner, Rafael Coveñas
Current Drug Abuse Reviews|October 26, 2017
Long-term Administration of Antipsychotic Drugs in Schizophrenia and Influence of Substance and Drug Abuse on the Disease OutcomeFelix-Martin Werner, Rafael Covenas
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Current Pharmaceutical Design|June 20, 2019
Neural Networks in Neurological and Psychiatric DiseasesFelix-Martin Werner
Current Pharmaceutical Design|January 29, 2016
Serotonergic Drugs: Agonists/Antagonists at Specific Serotonergic Subreceptors for the Treatment of Cognitive, Depressant and Psychotic Symptoms in Alzheimer's DiseaseFelix-Martin Werner, Rafael Covenas
Current Pharmaceutical Design|April 11, 2019
Therapeutic Effect of Novel Antidepressant Drugs Acting at Specific Receptors of Neurotransmitters and NeuropeptidesFelix-Martin Werner, Rafael Coveñas
The International Journal of Neuroscience|June 30, 2010
Classical neurotransmitters and neuropeptides involved in major depression: a reviewFelix-Martin Werner, Rafael Coveñas
Central Nervous System Agents in Medicinal Chemistry|January 27, 2026
Clinical Effects of Recently Developed Antipsychotic Drugs in SchizophreniaFelix-Martin Werner, Rafael Coveñas
Current Medicinal Chemistry|October 3, 2013
Classical neurotransmitters and neuropeptides involved in major depression in a multi-neurotransmitter system: a focus on antidepressant drugsFelix-Martin Werner, R Coveñas
Therapeutics and Clinical Risk Management|November 21, 2015
New developments in the management of schizophrenia and bipolar disorder: potential use of cariprazineFelix-Martin Werner, Rafael Coveñas
Current Pharmaceutical Design|December 11, 2020
The Novel Antipsychotic Drug Cariprazine and Cognition Enhancing Drugs: Indications for their Use as the Add-on Therapy in SchizophreniaFelix-Martin Werner, Rafael Coveñas
Current Drug Discovery Technologies|October 24, 2019
Risperidone: A Commentary on Drug ProfilingFelix-Martin Werner, Rafael Coveñas
Current Drug Abuse Reviews|October 26, 2017
Long-term Administration of Antipsychotic Drugs in Schizophrenia and Influence of Substance and Drug Abuse on the Disease OutcomeFelix-Martin Werner, Rafael Covenas
Pageof 2